Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

products or product candidates; -- the Company's ability to enter into and successfully execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the Company's ability to obtain sufficient financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company and its officers and directors and any proposed settlement of such litigation; -- the Company's ability to regain compliance with the NASDAQ's listing qualifications, or its ability to successfully appeal the NASDAQ delisting; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

     CONTACT:

     For Genta Incorporated

     Tara Spiess/Andrea Romstad

     TS Communications Group, LLC

     (908) 286-3980

     

info@genta.com

CONTACT: Tara Spiess or Andrea Romstad, both of TS Communications Group,LLC, +1-908-286-3980, , for Genta Incorporated info@genta.com

Web site: http://www.genta.com/http://www.idispharma.com/http://www.genta.com//

Ticker Symbol: (NASDAQ-NMS:GNTA)


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... March 16 Sigma-Aldrich® (Nasdaq: SIAL ) ... Ace Animals, Inc., a Berks County, PA. -based ... industry. Ace Animals ( www.aceanimals.com ), a commercial rodent ... contract breeding services, and will operate as part of ...
... , INDIANAPOLIS and MELBOURNE, Australia , ... (NYSE: LLY ) and Acrux (ASX: ACR) ... worldwide license agreement for the potential commercialization of Acrux,s ... drug application for AXIRON is currently under regulatory review ...
Cached Medicine Technology:Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 2Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 3Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 4Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 5Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 6Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 7Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 2Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 3Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 4Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 5
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... Montefiore Medical Center and the Albert ... present new findings at the Alzheimer,s Association International Conference ... Copenhagen, Denmark. Data from the four abstracts will focus ... to mild cognitive impairment and dementia. The research is ... in 1980 to examine healthy brain aging as well ...
(Date:7/9/2014)... and have a reputation for being highly toxic, but when ... being being found to offer potential health benefits in a ... dementia. A new compound (AP39), designed and made at the ... by targeting delivery of very small amounts of the substance ... Scientists in Exeter have already found that the compound protects ...
(Date:7/9/2014)... study conducted by researchers at Tufts University School of ... intellectual and developmental disabilities, the likelihood of having cavities ... increased. The findings, published in the July/August issue of ... interventions designed to address the oral health of individuals ... dental records of 107 patients at one of the ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... ... Areas, NEW YORK, March ... of Healthcare Providers and,Systems (HCAHPS) scores for hospitals nationwide on different aspects ... New York City scored well above the national average in both,overall patient ...
... Goal To Secure 1 Million Pledges By Independence ... the "Healing Starts With Us",national campaign launches its ... will mobilize and promote the campaign,s,goal to reach ... 2008., The campaign,s website comes after an ...
... Inc. (NYSE:,CNO) announced today that it has filed its ... 31, 2007 with the Securities and Exchange,Commission., The ... was $194.0,million, compared to the $210.1 million estimated by ... reported net loss applicable to,common stock for the fourth ...
... collateral damage from blood sugar disease , , FRIDAY, March ... of heart disease, stroke, blindness, kidney failure and non-traumatic ... than they normally do with age, a new study ... lung function as they grow older, research published in ...
... A child spikes a high fever, sometimes as high as ... to the emergency room, the hospital runs test after test, ... Many families though no one knows how many ... like clockwork, arent accompanied by any obvious symptoms and dont ...
... N.Y. -- For a rich source of stem cells to ... may one day look no further than the hair on ... month by University at Buffalo engineers. , Engineering ... blood vessels or regenerating new skin tissue using stem cells ...
Cached Medicine News:Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 2Health News:'Healing Starts With Us' National Campaign Commits to Battling Depression - By Any Means Necessary 3Health News:Conseco Files 10-K and Sets Earnings Release Date 2Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2
... Pneumoniae Antibody (IgG) Test is a semiquantitative ... clinically significant IgG antibodies to M. pneumoniae ... The test should not be used for ... Antibody (IgM) Test and is not intended ...
... is a qualitative enzyme immunoassay (EIA) ... virus capsid antigen (EBV-VCA), Epstein-Barr early ... Toxoplasma. When used in conjunction with ... in the serodiagnosis of infectious (EBV) ...
... ImmunoDOT TORCH Test is an ... for determining the presence of ... virus, cytomegalovirus and herpes simplex ... whole blood to indicate previous ...
... DotBlot G Tests are qualitative enzyme immunoassays ... burgdorferi antibodies (IgG or IgM, respectively) in ... tests should be supplemented with a standardized ... be used to support a clinical diagnosis ...
Medicine Products: